Tango Therapeutics, Inc. (TNGX): Price and Financial Metrics
GET POWR RATINGS... FREE!
TNGX POWR Grades
- Sentiment is the dimension where TNGX ranks best; there it ranks ahead of 84.88% of US stocks.
- TNGX's strongest trending metric is Stability; it's been moving up over the last 177 days.
- TNGX ranks lowest in Momentum; there it ranks in the 10th percentile.
TNGX Stock Summary
- With a one year PEG ratio of 0.47, TANGO THERAPEUTICS INC is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 4.24% of US stocks.
- TNGX's price/sales ratio is 24.96; that's higher than the P/S ratio of 94.76% of US stocks.
- With a year-over-year growth in debt of 467.16%, TANGO THERAPEUTICS INC's debt growth rate surpasses 96.24% of about US stocks.
- Stocks that are quantitatively similar to TNGX, based on their financial statements, market capitalization, and price volatility, are ALPN, IDYA, SGMO, BPMC, and GRTS.
- To dig deeper into the stock's financial statements, go to TNGX's page on browse-edgar?action=getcompany&CIK=0001819133.
TNGX Valuation Summary
- In comparison to the median Healthcare stock, TNGX's price/earnings ratio is 127.75% lower, now standing at -6.3.
- Over the past 29 months, TNGX's price/earnings ratio has gone up 5.4.
Below are key valuation metrics over time for TNGX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TNGX | 2023-01-20 | 26.5 | 2.3 | -6.3 | -5.8 |
| TNGX | 2023-01-19 | 26.8 | 2.4 | -6.4 | -5.8 |
| TNGX | 2023-01-18 | 27.1 | 2.4 | -6.5 | -5.9 |
| TNGX | 2023-01-17 | 28.9 | 2.6 | -6.9 | -6.3 |
| TNGX | 2023-01-13 | 29.4 | 2.6 | -7.0 | -6.5 |
| TNGX | 2023-01-12 | 29.2 | 2.6 | -7.0 | -6.4 |
TNGX Price Target
For more insight on analysts targets of TNGX, see our TNGX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $17.75 | Average Broker Recommendation | 1.2 (Strong Buy) |
TNGX Stock Price Chart Interactive Chart >
TNGX Price/Volume Stats
| Current price | $6.60 | 52-week high | $9.99 |
| Prev. close | $6.17 | 52-week low | $3.18 |
| Day low | $6.06 | Volume | 350,693 |
| Day high | $6.62 | Avg. volume | 164,090 |
| 50-day MA | $7.50 | Dividend yield | N/A |
| 200-day MA | $5.85 | Market Cap | 581.97M |
Tango Therapeutics, Inc. (TNGX) Company Bio
Tango Therapeutics, Inc., a biotechnology company, discovers and develops medicines for the treatment of cancer. Its lead program is TNG908, a protein arginine methyl transferase 5 inhibitor that is being developed as a treatment for cancers with MTAP deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor that treats cancers with BRCA1 mutations. Tango Therapeutics, Inc. has strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.
Latest TNGX News From Around the Web
Below are the latest news stories about TANGO THERAPEUTICS INC that investors may wish to consider to help them evaluate TNGX as an investment opportunity.
HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of DirectorsNEW YORK and VIENNA, Austria, Dec. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today the promotion of Katia Schlienger, M.D., Ph.D., to Chief Medical Officer and the appointment of Malte Peters, M.D., to its Board of Directors, both effective January 1, 2023. “Katia has had a major impact on HOOKIPA’s clinical development strategy and execution in immuno- |
H.C. Wainwright Sticks to Their Buy Rating for Tango Therapeutics (TNGX)In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Tango Therapeutics (TNGX - Research Report), with a price target of $10.00. The company's shares closed yesterday at $7.74.According to TipRanks, Burns is an analyst with an average return of -22.9% and a 22.68% success rate. Burns covers the Healthcare sector, focusing on stocks such as MacroGenics, Neoleukin Therapeutics, and Springworks Therapeutics.The word on The Street in general, suggests a Strong Buy analyst consensus rating for Tango Therapeutics with a $15.00 average price target, which is a 93.80% upside from current levels. |
Tango Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Highlights– Clinical Trial Application (CTA) for TNG908, an MTA-cooperative PRMT5 inhibitor, approved by the National Agency for the Safety of Medicines (ANSM) in France – – TNG260 disclosed as a first-in-class CoREST complex inhibitor for treatment of STK11-mutant cancers – – TNG348 declared as a USP1 inhibitor development candidate for treatment of BRCA1/2 mutant cancers – – Aaron Weitzman, M.D., F.A.C.P., appointed Chief Medical Officer – BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, In |
Tango Therapeutics to Participate in Upcoming Investor ConferencesBOSTON, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in the following upcoming investor conferences in November. H.C. Wainwright 3rd Annual Precision Oncology ConferenceDate: Monday, November 14, 2022Time: 11: |
Tango Therapeutics Announces Presentation of Preclinical Data on PRMT5 Inhibitors TNG908 and TNG462 in Three Abstracts Accepted at 34th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer TherapeuticsBOSTON, Oct. 19, 2022 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that three abstracts have been selected for presentation as posters at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, being held in Barcelona, Spain from October 26-28, 2022. Details on the Tango presentations at the EORTC-NCI-AACR Symposium are as follows: |
TNGX Price Returns
| 1-mo | -8.97% |
| 3-mo | -10.93% |
| 6-mo | 52.42% |
| 1-year | -22.63% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -8.97% |
| 2022 | -33.73% |
| 2021 | -4.37% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...